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Long  QT  syndrome  (LQTS)  is a hereditary  ion  channelopathy  resulting  in prolonged  cardiac  repolarization
and  abnormal  prolongation  of the QT interval  on the  electrocardiogram  (ECG).  The  patients  are  likely  to
develop  ventricular  arrhythmias  and  sudden  cardiac  death.  Molecular  biology  and  basic  electrophysiology
studies  revealed  an  approach  to the  management  of patients  with  LQTS,  which  includes  genotype-based
risk  stratiﬁcation.  A 16-year-old-woman  with  QT prolongation  on ECG had  frequent  syncopal  episodes
and  an  attack  of  ventricular  tachycardia  followed  by  ventricular  ﬁbrillation.  The  SCN5A  mutation  (intra-
vene  sequence  4-1  c/t)  in addition  to  the  KCNH2  mutation  (Arg56Gln)  was  identiﬁed.  Her mother  and
older  sister  were  also  diagnosed  as  having  LQTS,  but had  only  a single  mutation  (KCNH2).  Her older  sister
had an  episode  of  syncope,  but her mother  did  not.  Genetic  analysis  sometimes  reveals  2  or  more  muta-
tions in LQTS  patients  with  clinical  phenotypes  of the  Romano–Ward  syndrome.  Compound  mutations
in  different  LQTS-related  genes  are  likely  to  modify  clinical  characteristics.  In addition,  comprehensive
screening  of  LQTS-related  genes  might  be  needed  when  facing  family  members  with  different  clinical
manifestations.
<Learning  objective:  Molecular  biology  and basic  electrophysiology  studies  revealed  an  approach  to  the
management  of  patients  with  LQTS,  which  includes  genotype-based  risk  stratiﬁcation.  We  described  a
case of  LQTS  having  compound  mutations  of  KCNH2  and  SCN5A  who  had  frequent  syncopal  episodes  and
an attack  of  ventricular  ﬁbrillation.  The  mutations  of 2  different  genes  were  associated  with  a  severe
phenotype  of  LQTS.  Comprehensive  screening  of LQTS-related  genes  might  be  needed  for  estimating  the
severity of  LQTS.>
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The long QT syndrome (LQTS) is a genetic cardiac channelopathy
n which most affected individuals have delayed ventricular repo-
arization manifested with prolongation of the corrected QT (QTc)
nterval on the electrocardiogram (ECG) [1–3]. Clinically, this con-
ition can lead to ventricular arrhythmias with syncope and sudden
eath. LQTS is caused by disturbed function of ion channel subunits
r proteins. Ion channels have speciﬁc ion selectivity and allow
he passage of charged ions across the cell membrane [3].  Expres-
ion of abnormal sodium, calcium, or potassium channels results
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in aberrant ionic ﬂuxes that can delay ventricular repolarization,
manifesting as a prolonged QT intervals [2].
Congenital LQTS is identiﬁed as the Romano–Ward syndrome
(prolonged QT interval, autosomal dominant transmission) and
the much rarer Jervell and Lange–Nielsen syndrome (prolonged
QT interval with deafness, autosomal recessive transmission) syn-
dromes [1]. To date, 15 subtypes, including 13 of the Romano–Ward
syndrome and 2 of the Jervell and Lange–Nielsen syndrome, caused
by 13 genes with >1200 mutations have been identiﬁed [3].  Muta-
tions in KCNQ1, KCNH2,  and SCN5A,  underlying the LQTS type 1, 2,
and 3, respectively, account for 90–95% among the LQTS cases [1].
Gene-speciﬁc clinical features have been well recognized in LQTS.
In particular, these 3 genetic variants have different features, risks,
and responses to therapy. Patients with LQT1 have more sensitivity
to sympathetic stimulation than those with LQT2 or LQT3 [4].  The
trigger of Torsade de Pointes (TdP) for patients having LQT1, LQT2,
vier Ltd. All rights reserved.
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to her sister and her mother. These suggested that patients with
compound mutations might occur earlier than those with a single
mutation.ig. 1. Electrocardiographic (ECG) ﬁndings of the patient’s clinical course. (a) 12-le
ith  notches. (b) Torsades de pointes (TdP) ventricular tachycardia during syncope
nd LQT3 is exercise, startle status, and sleep/rest, respectively
4]. A beta-blocker is the ﬁrst choice of pharmacological therapy
n LQT1 and LQT2 patients. A class IB sodium channel blocker is
ffective in the LQT3 syndrome [4].
Some patients with clinical phenotypes of the Romano–Ward
yndrome have multiple mutations in LQTS-related genes. Herein,
e report a case of LQTS with 2 mutations, i.e. KCNH2 and SCN5A.
ase report
A 16-year-old female was admitted to our hospital due to fre-
uent and severe syncopal episodes. When she was  10 years’ old,
he fainted and QTc prolongation was detected on the ECG. At that
ime, she was diagnosed as having LQT2 syndrome on the basis of
ypical abnormal ﬁndings on the ECG and detection of the KCNH2
utation (Arg56Gln). At the age of 15 years, she started to have
yncopal episodes with spontaneous resolution (within 1 min). The
vents were provoked at the time of waking up by her alarm clock,
uring urination, or during conversations with her friends. The
CG showed prolonged QTc intervals (512 ms)  and low-amplitude
 waves with notches, which are typical for LQT2 (Fig. 1a) [3].
On admission, she had syncope with TdP ventricular tachycar-
ia (VT) which reverted to sinus rhythm within 1 min. Although
ropranolol had been administered immediately, another TdP
ccurred and deteriorated into ventricular ﬁbrillation (VF) (Fig. 1b
nd c). VF reverted to sinus rhythm within a few minutes by
ardiopulmonary resuscitation. After administration of bisoprolol,
erapamil, magnesium sulfate, and potassium, VT disappeared. In
ddition to bisoprolol and verapamil, an implantable cardioverter
eﬁbrillator (ICD) was implanted for atrial pacing and prevention
f sudden death [3,4].
We  also examined her family in detail. Her mother and her older
ister had QTc prolongations, although her father had normal QTc
nterval (Fig. 2a–c). Her older sister had an episode of syncope at the
ge of 18 years, but her father and mother did not. We  analyzed her
amily by genetic screening for gene mutations of LQTS, including
CNQ1 (LQT1), KCNH2 (LQT2), and SCN5A (LQT3), after informed con-
ent was given. A heterozygous mutation of KCNH2 (Arg56Gln) was
ound in her mother and older sister. Surprisingly, the SCN5A muta-
ion (intravene sequence (IVS) 4-1 c/t) in addition to the KCNH2
utation (Arg56Gln) was identiﬁed in the patient (Fig. 3).
iscussion
Genetic analysis sometimes reveals 2 or more mutations in LQTS
atients with clinical phenotypes of the Romano–Ward syndrome
5–8]. The prevalence of compound mutations is not rare, i.e. 4–11%
f genotyped LQTS patients [5–8]. Patients with compound muta-
ions are reported to have a more severe phenotype and younger
ge at onset than patients with a single mutation [5–7]. Our patient
ad 2 mutations, i.e. in the KCNH2 (LQT2), and SCN5A (LQT3) genes.G at rest showing a prolonged QTc interval of 512 ms  and low-amplitude T waves
P deteriorated into ventricular ﬁbrillation.
Her ﬁrst event occurred at the age of 10 years and her clinical
manifestation was prominent (electrical storm and VF) comparedFig. 2. Familial electrocardiographic (ECG) ﬁndings. ECG of her sister, showing a
prolonged QTc interval of 557 ms. ECG of her mother, showing a prolonged QTc
interval of 711 ms.  ECG of her father. QTc interval was  not prolonged.
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fig. 3. The pedigree of the patient. Arrow indicates a proband. Closed circles indicate
Tc prolongation in electrocardiogram.
Regarding treatment, the ﬁrst and second choice of pharma-
ological therapy in LQT1 and LQT2 patients was a beta-blocker
nd verapamil, respectively [4].  Mexiletine, a class IB sodium chan-
el blocker, is effective in the LQT3 syndrome [4].  Bisoprolol was
dministered because our case had been considered to be a LQT2.
his drug, however, was not effective, so verapamil was  added to
isoprolol, resulting in the success of VT suppression. We  did not
se mexiletine, a ﬁrst line of therapy in LQT3 patients, since her QTc
nterval was shortened by verapamil and bisoprolol. Some non-
esponders to beta-blockers among genetically diagnosed LQT1
atients have additional gene mutations [9].  It suggested that com-
ound mutations in different LQTS-related genes might modify the
esponse to treatment.
The KCNH2 mutation, Arg56Gln, which was found in our case,
ad previously been reported [10]. Mutations in KCNH2 which
ncodes the rapidly activating delayed rectiﬁer K + current (IKr)
hannel, cause loss of the channel function, thus resulting in
educed outward current during the repolarization phase of the car-
iac action potential and causing prolongation of the QTc interval
2,3]. On the other hand, the splicing error of SCN5A mutation, IVS4-
 c/t, has not been reported, so we could not exactly understand the
unction of this mutation. This mutation, however, is speculated to
[ Cases 6 (2012) e170–e172
induce a splicing error, resulting in a truncated protein that might
lead to gain of function of SCN5A increasing the sodium current (INa)
leading to prolongation of the cardiac action potential [4,7].
The mutations of 2 different genes in our patient were asso-
ciated with a severe phenotype of LQTS. She was diagnosed as
LQT2 with the KCNH2 mutation at the age of 10 years. At that
time, the screening of other genes was canceled because detec-
tion of the KCNH2 mutation was regarded as sufﬁcient. However,
she was  found to have the SCN5A mutation as well as the KCNH2
mutation. It might not be appropriate to stop the screening for
several LQTS-associated genes, if one LQTS mutation has been iden-
tiﬁed, because this might result in underestimating the severity
of LQTS. Comprehensive screening of LQTS-related genes might
be needed when facing family members with different clinical
manifestations.
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